HOMOLA, Lukáš, Jozef KLUČKA, Dominik FABIÁN, Petr ŠTOURAČ, Josef ŠIKULA, Eva VÁVROVÁ, Barbora JEŘÁBKOVÁ, Martin SIHLOVEC, Václav MUSIL, Klára ŠPANĚLOVÁ, Patrícia MUŽLAYOVÁ a Pavlína DANHOFER. Causes of Intensive Care Unit Admissions in Children with SARS-CoV-2: Single-Centre Observational Study. Children. Basel: MDPI, 2023, roč. 10, č. 1, s. 1-15. ISSN 2227-9067. Dostupné z: https://dx.doi.org/10.3390/children10010075.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Causes of Intensive Care Unit Admissions in Children with SARS-CoV-2: Single-Centre Observational Study
Autoři HOMOLA, Lukáš (203 Česká republika, domácí), Jozef KLUČKA (703 Slovensko, domácí), Dominik FABIÁN (203 Česká republika, domácí), Petr ŠTOURAČ (203 Česká republika, domácí), Josef ŠIKULA (203 Česká republika), Eva VÁVROVÁ (203 Česká republika), Barbora JEŘÁBKOVÁ (203 Česká republika), Martin SIHLOVEC (703 Slovensko), Václav MUSIL (203 Česká republika, domácí), Klára ŠPANĚLOVÁ (203 Česká republika), Patrícia MUŽLAYOVÁ (703 Slovensko, domácí) a Pavlína DANHOFER (203 Česká republika, garant, domácí).
Vydání Children, Basel, MDPI, 2023, 2227-9067.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30221 Critical care medicine and Emergency medicine
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.400 v roce 2022
Kód RIV RIV/00216224:14110/23:00130328
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/children10010075
UT WoS 000917039700001
Klíčová slova anglicky COVID-19; SARS-CoV-2; children; intensive care; ICU; MIS-C; isolation
Štítky 14110318, 14110320, 14110322, 14110528, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 11. 7. 2023 11:06.
Anotace
Background: The proportion of intensive care unit (ICU) admissions in children that have and have not been directly caused by SARS-CoV-2 remains unclear. The aim of the study is to analyse a cohort of children admitted to the ICU with SARS-CoV-2 and determine whether the infection was the primary cause of their hospitalisation, a significant contributor, a suspected accomplice, or an incidental finding. Methods: This was a retrospective observational study of all the children admitted to the ICU with SARS-CoV-2 from March 2020 to February 2022 from the South Moravia region. The aim of the study was to assess whether the hospitalisation was likely to be directly caused by the virus (i.e., patients with acute COVID-19; the COVID group), whether the virus was a significant contributor to the hospitalisation (i.e., patients with multisystem inflammatory syndrome in children due to COVID-19; the MIS-C group), whether it may have contributed to the worsening of their underlying disease (the WORSENING group), or whether it was an incidental finding very likely unrelated to hospitalisation where SARS-CoV-2 positivity merely placed patients in the COVID-19 unit (the ISOLATION group). The groups were compared using a series of secondary outcomes. Results: The study population represented 150 paediatric ICU cases (age 8.6; IQR 3.5–13.3 years), with 66.7% being male. The COVID group represented 32.7% of cases (49/150); MIS-C, 30% (45/150); WORSENING, 14.7% (22/150); and ISOLATION, 22.7% (34/150). The median length of hospitalisation was found for the MIS-C group (11 days; 9 days in the ICU), the COVID group (6 days; five days in the ICU), WORSENING group (4.5 days; 4.5 days in the ICU) and the ISOLATION group (5.5 days; 3.5 days in the ICU), where the difference was significant (p < 0.001). Asymptomatic and mild cases were most common in the WORSENING (36.4% and 63.6%) and ISOLATION (52.9% and 44.1%) groups. Severe and critical cases were only present in the COVID (6.1% and 12.2%) and MIS-C (4.4% and 11.1%) groups; the severity difference was significant (p < 0.001). The groups did not differ significantly in the proportion of complete recovery and short- and long-term sequelae (p = 0.09).
Návaznosti
MUNI/A/1404/2021, interní kód MUNázev: Imunita u dětí po Covid-19 (Akronym: ImunCovid)
Investor: Masarykova univerzita, Imunita u dětí po Covid-19
VytisknoutZobrazeno: 18. 7. 2024 01:18